Additional information received indicates that the device is not available for return, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A manufacturing record evaluation was performed for the finished device 31038217l number, and no internal actions related to the complaint was found during the review.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's reference number: (b)(4).
|
During a clinical trial, it was reported that a patient underwent an atrial fibrillation (afib) procedure with a thermocool® smart touch® sf bi-directional navigation catheter and suffered heart failure, which required prolonged hospitalization.Patient received a cardiac index ablation on (b)(6) 2023 under conscious sedation.On (b)(6) 2023, patient experienced heart failure categorized as moderate and is considered a serious injury due to serious deterioration in the health of the subject as defined by prolonged hospitalization (admission date (b)(6) 2023 and discharged (b)(6) 2023).Relationship to study device is not related and relationship to primary study procedure is possible relationship to the index procedure.The adverse event is unexpected/unanticipated.The outcome is recovered/resolved.Intervention was medication.Bmi 24.4 kg.M2.
|
In the 3500a initial under the d10.Concomitant medical products and therapy dates section, the agilis sheath was listed as it was reported as a concomitant product.Additional information was received on 05-jan-2024 inactivating the agilis sheath for this complaint.Therefore, it is no longer considered a concomitant product.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's reference number: (b)(4).
|